
Targeted Drugs for Parkinson's Disease Industry Research Report 2025
Description
Summary
According to APO Research, The global Targeted Drugs for Parkinson's Disease market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Targeted Drugs for Parkinson's Disease include Acadia Pharmaceuticals Inc., Supernus Pharmaceuticals, UCB, Kyowa Kirin and Sumitomo Pharma Co., Ltd., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Parkinson's Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Parkinson's Disease.
The Targeted Drugs for Parkinson's Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Targeted Drugs for Parkinson's Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Targeted Drugs for Parkinson's Disease Segment by Company
Acadia Pharmaceuticals Inc.
Supernus Pharmaceuticals
UCB
Kyowa Kirin
Sumitomo Pharma Co., Ltd.
Targeted Drugs for Parkinson's Disease Segment by Type
Patch
Capsule
Other
Targeted Drugs for Parkinson's Disease Segment by Application
Hospital
Clinic
Other
Targeted Drugs for Parkinson's Disease Segment by Application
Hospital
Clinic
Other
Targeted Drugs for Parkinson's Disease Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Parkinson's Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Parkinson's Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Parkinson's Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Targeted Drugs for Parkinson's Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Targeted Drugs for Parkinson's Disease market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Targeted Drugs for Parkinson's Disease is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Targeted Drugs for Parkinson's Disease include Acadia Pharmaceuticals Inc., Supernus Pharmaceuticals, UCB, Kyowa Kirin and Sumitomo Pharma Co., Ltd., etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Targeted Drugs for Parkinson's Disease, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted Drugs for Parkinson's Disease.
The Targeted Drugs for Parkinson's Disease market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Targeted Drugs for Parkinson's Disease market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Targeted Drugs for Parkinson's Disease Segment by Company
Acadia Pharmaceuticals Inc.
Supernus Pharmaceuticals
UCB
Kyowa Kirin
Sumitomo Pharma Co., Ltd.
Targeted Drugs for Parkinson's Disease Segment by Type
Patch
Capsule
Other
Targeted Drugs for Parkinson's Disease Segment by Application
Hospital
Clinic
Other
Targeted Drugs for Parkinson's Disease Segment by Application
Hospital
Clinic
Other
Targeted Drugs for Parkinson's Disease Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted Drugs for Parkinson's Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted Drugs for Parkinson's Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted Drugs for Parkinson's Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Targeted Drugs for Parkinson's Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
117 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Targeted Drugs for Parkinson's Disease by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 Patch
- 2.2.3 Capsule
- 2.2.4 Other
- 2.3 Targeted Drugs for Parkinson's Disease by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Other
- 2.4 Assumptions and Limitations
- 3 Targeted Drugs for Parkinson's Disease Breakdown Data by Type
- 3.1 Global Targeted Drugs for Parkinson's Disease Historic Market Size by Type (2020-2025)
- 3.2 Global Targeted Drugs for Parkinson's Disease Forecasted Market Size by Type (2026-2031)
- 4 Targeted Drugs for Parkinson's Disease Breakdown Data by Application
- 4.1 Global Targeted Drugs for Parkinson's Disease Historic Market Size by Application (2020-2025)
- 4.2 Global Targeted Drugs for Parkinson's Disease Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Targeted Drugs for Parkinson's Disease Market Perspective (2020-2031)
- 5.2 Global Targeted Drugs for Parkinson's Disease Growth Trends by Region
- 5.2.1 Global Targeted Drugs for Parkinson's Disease Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Targeted Drugs for Parkinson's Disease Historic Market Size by Region (2020-2025)
- 5.2.3 Targeted Drugs for Parkinson's Disease Forecasted Market Size by Region (2026-2031)
- 5.3 Targeted Drugs for Parkinson's Disease Market Dynamics
- 5.3.1 Targeted Drugs for Parkinson's Disease Industry Trends
- 5.3.2 Targeted Drugs for Parkinson's Disease Market Drivers
- 5.3.3 Targeted Drugs for Parkinson's Disease Market Challenges
- 5.3.4 Targeted Drugs for Parkinson's Disease Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Targeted Drugs for Parkinson's Disease Players by Revenue
- 6.1.1 Global Top Targeted Drugs for Parkinson's Disease Players by Revenue (2020-2025)
- 6.1.2 Global Targeted Drugs for Parkinson's Disease Revenue Market Share by Players (2020-2025)
- 6.2 Global Targeted Drugs for Parkinson's Disease Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Targeted Drugs for Parkinson's Disease Head Office and Area Served
- 6.4 Global Targeted Drugs for Parkinson's Disease Players, Product Type & Application
- 6.5 Global Targeted Drugs for Parkinson's Disease Manufacturers Established Date
- 6.6 Global Targeted Drugs for Parkinson's Disease Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Targeted Drugs for Parkinson's Disease Market Size (2020-2031)
- 7.2 North America Targeted Drugs for Parkinson's Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Targeted Drugs for Parkinson's Disease Market Size by Country (2020-2025)
- 7.4 North America Targeted Drugs for Parkinson's Disease Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Targeted Drugs for Parkinson's Disease Market Size (2020-2031)
- 8.2 Europe Targeted Drugs for Parkinson's Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Targeted Drugs for Parkinson's Disease Market Size by Country (2020-2025)
- 8.4 Europe Targeted Drugs for Parkinson's Disease Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size (2020-2031)
- 9.2 Asia-Pacific Targeted Drugs for Parkinson's Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Targeted Drugs for Parkinson's Disease Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Targeted Drugs for Parkinson's Disease Market Size (2020-2031)
- 10.2 South America Targeted Drugs for Parkinson's Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Targeted Drugs for Parkinson's Disease Market Size by Country (2020-2025)
- 10.4 South America Targeted Drugs for Parkinson's Disease Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Targeted Drugs for Parkinson's Disease Market Size (2020-2031)
- 11.2 Middle East & Africa Targeted Drugs for Parkinson's Disease Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Targeted Drugs for Parkinson's Disease Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Targeted Drugs for Parkinson's Disease Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 Acadia Pharmaceuticals Inc.
- 12.1.1 Acadia Pharmaceuticals Inc. Company Information
- 12.1.2 Acadia Pharmaceuticals Inc. Business Overview
- 12.1.3 Acadia Pharmaceuticals Inc. Revenue in Targeted Drugs for Parkinson's Disease Business (2020-2025)
- 12.1.4 Acadia Pharmaceuticals Inc. Targeted Drugs for Parkinson's Disease Product Portfolio
- 12.1.5 Acadia Pharmaceuticals Inc. Recent Developments
- 12.2 Supernus Pharmaceuticals
- 12.2.1 Supernus Pharmaceuticals Company Information
- 12.2.2 Supernus Pharmaceuticals Business Overview
- 12.2.3 Supernus Pharmaceuticals Revenue in Targeted Drugs for Parkinson's Disease Business (2020-2025)
- 12.2.4 Supernus Pharmaceuticals Targeted Drugs for Parkinson's Disease Product Portfolio
- 12.2.5 Supernus Pharmaceuticals Recent Developments
- 12.3 UCB
- 12.3.1 UCB Company Information
- 12.3.2 UCB Business Overview
- 12.3.3 UCB Revenue in Targeted Drugs for Parkinson's Disease Business (2020-2025)
- 12.3.4 UCB Targeted Drugs for Parkinson's Disease Product Portfolio
- 12.3.5 UCB Recent Developments
- 12.4 Kyowa Kirin
- 12.4.1 Kyowa Kirin Company Information
- 12.4.2 Kyowa Kirin Business Overview
- 12.4.3 Kyowa Kirin Revenue in Targeted Drugs for Parkinson's Disease Business (2020-2025)
- 12.4.4 Kyowa Kirin Targeted Drugs for Parkinson's Disease Product Portfolio
- 12.4.5 Kyowa Kirin Recent Developments
- 12.5 Sumitomo Pharma Co., Ltd.
- 12.5.1 Sumitomo Pharma Co., Ltd. Company Information
- 12.5.2 Sumitomo Pharma Co., Ltd. Business Overview
- 12.5.3 Sumitomo Pharma Co., Ltd. Revenue in Targeted Drugs for Parkinson's Disease Business (2020-2025)
- 12.5.4 Sumitomo Pharma Co., Ltd. Targeted Drugs for Parkinson's Disease Product Portfolio
- 12.5.5 Sumitomo Pharma Co., Ltd. Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.